Pharminent

Pfizer taps Sangamo for hemophilia gene therapy

The deal validates Sangamo’s gene therapy technology and provides Pfizer with another gene therapy in the hemophilia space.  http://www.biopharmadive.com/news/pfizer-sangamo-hemophilia-gene-therapy/442527/

Filed under: Company